Charles S Fuchs

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Electronic address
    Lancet 383:31-9. 2014
  2. pmc Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:8263-9. 2008
  3. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
  4. pmc Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:4591-8. 2009
  5. pmc Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial
    Shuji Ogino
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF Department of Pathology SO, Channing Division of Network Medicine, Department of Medicine DS, CSF, and Department of Surgery MMB, Brigham and Women s Hospital and Harvard Medical School, Boston, MA SO Department of Epidemiology SO, DS and Department of Biostatistics DS, Harvard School of Public Health, Boston, MA Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC DN Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital du Sacré Coeur de Montréal, Montreal, Canada RW Loyola University Stritch School of Medicine, Maywood, IL AH current Edward Cancer Center, Naperville, IL AH Northwestern University, Chicago, IL ABB Toledo Community Hospital Oncology Program, Toledo, OH RBM Division of Medical Oncology, Germany
    J Natl Cancer Inst 105:1789-98. 2013
  6. pmc Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mol Cancer 9:125. 2010
  7. pmc CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival
    Ron Firestein
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Int J Cancer 126:2863-73. 2010
  8. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
  9. pmc Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1599-606. 2011
  10. pmc Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009

Collaborators

Detail Information

Publications127 found, 100 shown here

  1. doi request reprint Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Electronic address
    Lancet 383:31-9. 2014
    ..We aimed to assess whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, prolonged survival in patients with advanced gastric cancer...
  2. pmc Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741
    Charles S Fuchs
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:8263-9. 2008
    ..We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer...
  3. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  4. pmc Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:4591-8. 2009
    ..However, it is unclear whether 18q LOH in colorectal cancer has any prognostic implication independent of MSI status and other potential predictors of clinical outcome...
  5. pmc Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial
    Shuji Ogino
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA SO, XL, YI, MY, NJM, KN, RJM, JAM, CSF Department of Pathology SO, Channing Division of Network Medicine, Department of Medicine DS, CSF, and Department of Surgery MMB, Brigham and Women s Hospital and Harvard Medical School, Boston, MA SO Department of Epidemiology SO, DS and Department of Biostatistics DS, Harvard School of Public Health, Boston, MA Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC DN Memorial Sloan Kettering Cancer Center, New York, NY LBS Hôpital du Sacré Coeur de Montréal, Montreal, Canada RW Loyola University Stritch School of Medicine, Maywood, IL AH current Edward Cancer Center, Naperville, IL AH Northwestern University, Chicago, IL ABB Toledo Community Hospital Oncology Program, Toledo, OH RBM Division of Medical Oncology, Germany
    J Natl Cancer Inst 105:1789-98. 2013
    ..Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer...
  6. pmc Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mol Cancer 9:125. 2010
    ..Thus, it is of particular interest to examine whether its wide variation can be attributed to clinical, pathologic or molecular features...
  7. pmc CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival
    Ron Firestein
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Int J Cancer 126:2863-73. 2010
    ..These data support a potential link between CDK8 and beta-catenin, and suggest that CDK8 may identify a subset of colon cancer patients with a poor prognosis...
  8. ncbi request reprint CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Virchows Arch 450:529-37. 2007
    ..Additional studies are necessary to examine the role of DNA methylation in treatment efficacy...
  9. pmc Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 29:1599-606. 2011
    ....
  10. pmc Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer
    Shoko Kure
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:2765-72. 2009
    ..Our data support potential interactions between the VDR, RAS-MAPK and PI3K-AKT pathways, and possible influence by KRAS or PIK3CA mutation on therapy or chemoprevention targeting VDR...
  11. pmc A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Gastroenterology 137:1609-20.e1-3. 2009
    ..Synchronous colon cancers have not been compared with control solitary cancers in a prospective study...
  12. ncbi request reprint A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Dig Dis Sci 50:2218-23. 2005
    ..When used as a single-agent, a tri-weekly schedule may be preferable for this patient population...
  13. pmc Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer
    Brian M Wolpin
    Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1027-35. 2013
    ..Hemoglobin A1c (HbA1c) is a measure of hyperglycemia, whereas plasma insulin and proinsulin are markers of peripheral insulin resistance, and the proinsulin to insulin ratio marks pancreatic β-cell dysfunction...
  14. pmc Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States
    Eur J Cancer 48:3405-13. 2012
    ..However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive colorectal cancers remain uncertain...
  15. ncbi request reprint MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Carcinogenesis 28:1985-90. 2007
    ..56C>T) of the MGMT promoter and promoter methylation/silencing of MGMT in colorectal cancer. Our data provide compelling evidence for common susceptibility for MGMT promoter CpG island methylation...
  16. pmc Tumor TP53 expression status, body mass index and prognosis in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Medicine Brigham and Women s Hospital, Boston, MA 02215, USA
    Int J Cancer 131:1169-78. 2012
    ..These molecular pathological epidemiology data may support a dual role of TP53 alterations in cell-cycle deregulation and cell autonomy with respect to energy balance status...
  17. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  18. pmc DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:3663-71. 2009
    ..We hypothesized that cellular DNMT3B level might influence the occurrence of widespread CpG island methylation (i.e., the CpG island methylator phenotype, CIMP) in colon cancer...
  19. pmc PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 10:534-41. 2008
    ..In addition, Pyrosequencing is useful in detecting PIK3CA mutation in archival paraffin tumor tissue. PIK3CA mutational data further emphasize heterogeneity of colorectal cancer at the molecular level...
  20. pmc Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer
    Aditi Hazra
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Causes Control 21:331-45. 2010
    ..Collectively, these exploratory data provide suggestive evidence for the association of MTHFR 429 Ala/ Ala and TCN2 259 Arg/Arg and CIMP status in colorectal cancer...
  21. ncbi request reprint Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:648-57. 2004
    ..To study the relationship between body mass index (BMI) and rates of sphincter-preserving operations, overall survival, cancer recurrence, and treatment-related toxicities in patients with rectal cancer...
  22. pmc Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1702-11. 2012
    ..The influence of glycemic load and related measures on survival among colon cancer patients remains largely unknown...
  23. pmc PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:1477-84. 2009
    ..PIK3CA mutation and subsequent activation of the AKT pathway play an important role in colorectal carcinogenesis. However, little is known about the prognostic role of PIK3CA mutation in colon cancer...
  24. pmc Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:176-85. 2009
    ..Excess energy balance leads to increased circulating insulin and depressed levels of circulating insulin-like growth factor binding protein (IGFBP) -1, which promote cancer cell growth in preclinical models...
  25. pmc IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 9:1091-8. 2007
    ..Our data suggest complex relationship between global genomic/epigenomic phenomena (such as MSI/CIMP), single molecular events (e.g., IGFBP3 methylation, TP53 mutation, and TGFBR2 mutation), and the related pathways...
  26. pmc Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
    JAMA 305:1685-94. 2011
    ..Alterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases...
  27. pmc Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    PLoS ONE 3:e3698. 2008
    ..In stratified analyses, the relations of CIMP-high with poor differentiation, KRAS mutation and LINE-1 hypomethylation significantly differed according to MSI status...
  28. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  29. pmc KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:7322-9. 2009
    ..It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer patients independent of anti-EGFR therapy...
  30. pmc Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 105:420-33. 2010
    ....
  31. ncbi request reprint Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:401-6. 2006
    ..We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors...
  32. pmc A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer
    Raaj S Mehta
    Affiliations of authors Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA RSM, ATC Gastrointestinal Research Group, Institute of Medical Sciences, Aberdeen University, Aberdeen, United Kingdom NB Department of Epidemiology XG, SO, ELG and Department of Nutrition MS, KW, XG, ELG, Harvard School of Public Health, Boston, MA Department of Pathology, University of Tokyo, Tokyo, Japan TM Channing Division of Network Medicine, Department of Medicine CSF, ELG, ATC and Department of Pathology SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA CSF, SO
    J Natl Cancer Inst 106:dju016. 2014
    ..Chronic inflammation plays a role in the development of colorectal cancer (CRC). The novel plasma inflammatory biomarker macrophage inhibitory cytokine-1 (MIC-1, GDF15) may have a direct mechanistic role in colorectal carcinogenesis...
  33. pmc Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial
    Kimmie Ng
    Department of Medical Oncology KN, JAM, and CSF and Center for Community Based Research JBS, EG S, and KME, Dana Farber Cancer Institute, Boston, MA the Division of Public Health Sciences, Washington University School of Medicine, St Louis, MO BFD the Division of Gastroenterology, Massachusetts General Hospital, Boston, MA ATC the Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA ATC, ELG, and CSF the Division of Pediatrics, Medical University of South Carolina, Charleston, SC BWH the Division of General Medicine, Brigham and Women s Hospital, Boston, MA PDC the Department of Psychology and Neuroscience, Duke University, Durham, NC GGB and the Departments of Nutrition JBS and ELG and Social and Behavioral Sciences KME, Harvard School of Public Health, Boston, MA
    Am J Clin Nutr 99:587-98. 2014
    ..Nonetheless, the relation between vitamin D supplementation and 25(OH)D concentrations in African Americans remains undefined...
  34. pmc A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification
    Reiko Nishihara
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Epidemiology, Harvard School of Public Health, 450 Brookline Avenue, Room JF 215C, Boston, MA 02215, USA
    Am J Epidemiol 178:84-100. 2013
    ..These molecular pathological epidemiology data suggest a protective effect of smoking cessation on a DNA methylation-related carcinogenesis pathway leading to CIMP-high colorectal cancer. ..
  35. pmc Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1151-6. 2013
    ..No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification...
  36. pmc Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers
    Yu Imamura
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Room JF 215C, Boston, MA 02215, USA
    Clin Cancer Res 18:4753-63. 2012
    ....
  37. pmc Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
    Arch Surg 147:715-23. 2012
    ..To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons...
  38. pmc Prospective cohort studies of vitamin B-6 intake and colorectal cancer incidence: modification by time?
    Xuehong Zhang
    Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am J Clin Nutr 96:874-81. 2012
    ..The relation between vitamin B-6 intake and colorectal cancer risk remains uncertain...
  39. pmc TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25062. 2011
    ..However, a role of TGFBR2 or BAX mononucleotide mutation in colorectal cancer as a prognostic biomarker remains uncertain...
  40. pmc Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:890-900. 2012
    ..We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer...
  41. pmc Aurora-A expression is independently associated with chromosomal instability in colorectal cancer
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 11:418-25. 2009
    ..In conclusion, AURKA overexpression is independently associated with CIN in colorectal cancer, supporting a potential role of Aurora kinase-A in colorectal carcinogenesis through genomic instability (rather than epigenomic instability)...
  42. pmc Interaction of molecular markers and physical activity on mortality in patients with colon cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5931-6. 2009
    ..Physical activity in colon cancer survivors has been associated with lower cancer recurrences and improved survival. Whether molecular features of the tumor portend more or less likelihood for benefit from exercise is unknown...
  43. pmc JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Neoplasia 11:87-95. 2009
    ..JCVT was unrelated with patient survival. In conclusion, JCVT expression in colorectal cancer is independently associated with p53 expression and CIN, which may lead to uncontrolled cell proliferation...
  44. pmc Cohort study of fatty acid synthase expression and patient survival in colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:5713-20. 2008
    ..Fatty acid synthase (FASN) is physiologically regulated by energy balance and is often upregulated in colorectal cancer. Nonetheless, the influence of FASN expression on patient outcome is uncertain...
  45. ncbi request reprint WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Takako Kawasaki
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Mod Pathol 21:150-8. 2008
    ..Our data suggest a possible role of WRN methylation in mucinous differentiation, and may provide explanation to the enigmatic association between mucin and MSI/CIMP...
  46. doi request reprint CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Mod Pathol 21:245-55. 2008
    ..Our data may provide supporting evidence for a difference in pathogenesis of DNA methylation between CIMP-low and CIMP-high tumors...
  47. pmc Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer
    Yoshifumi Baba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4665-73. 2009
    ....
  48. pmc CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 USA
    Gut 58:90-6. 2009
    ..The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain...
  49. pmc SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
    Katsuhiko Nosho
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Mod Pathol 22:922-32. 2009
    ..In conclusion, SIRT1 expression is associated with CIMP-high MSI-high colon cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype...
  50. ncbi request reprint Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 298:754-64. 2007
    ..Dietary factors have been associated with the risk of developing colon cancer but the influence of diet on patients with established disease is unknown...
  51. pmc Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Mol Diagn 9:305-14. 2007
    ..In conclusion, a panel of markers including at least RUNX3, CACNA1G, IGF2, and MLH1 can serve as a sensitive and specific marker panel for CIMP-high...
  52. pmc MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Causes Control 22:301-9. 2011
    ..MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain...
  53. pmc NRAS mutations are rare in colorectal cancer
    Natsumi Irahara
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Diagn Mol Pathol 19:157-63. 2010
    ..NRAS mutations were detected in 5 (2.2%) of the 225 colorectal cancers and tended to occur in left-sided cancers arising in women, but did not seem to be associated with any of the molecular features that were examined...
  54. pmc Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803
    Kimmie Ng
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Natl Cancer Inst 103:1540-51. 2011
    ..Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown...
  55. ncbi request reprint Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 11:6650-6. 2005
    ..Abnormalities of EGFR and related pathways may have an effect on responsiveness of advanced colorectal cancer to combination chemotherapy with gefitinib...
  56. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  57. pmc Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer
    Mai Yamauchi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 22:1142-52. 2013
    ....
  58. pmc Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations
    Hongmei Nan
    Affiliations of authors Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD HN Channing Division of Network Medicine, Department of Medicine HN, DJH, ELG, CSF, ATC and Department of Epidemiology DJH, PK, ELG, SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Center for Molecular Oncologic Pathology TM, YI, AK, MY, SO, Department of Medical Oncology TM, MS, YI, AK, MY, CSF, SO, MLF, and Department of Biostatistics and Computational Biology LW, Dana Farber Cancer Institute, Boston, MA Department of Epidemiology DJH, ELG, SO and Department of Nutrition, Harvard School of Public Health, Boston, Simancas 47130
    J Natl Cancer Inst 105:1852-61. 2013
    ....
  59. ncbi request reprint A phase II study of docetaxel in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Invest 22:353-9. 2004
    ..Twenty-one patients with metastatic carcinoid tumors were treated with docetaxel. Although the treatment was well tolerated, no objective radiologic responses were observed. Novel, more effective agents are needed for this disease...
  60. ncbi request reprint Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:484-95. 2003
    ..Obesity is a risk factor for the development of colon carcinoma. The influence of body mass index (BMI) on long-term outcomes and treatment-related toxicity in patients with colon carcinoma has not been well characterized...
  61. pmc Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Rm JF 215C, Boston, MA 02215, USA
    J Natl Cancer Inst 105:130-40. 2013
    ..We tested the hypothesis that CRC family history might confer a higher risk of LINE-1 methylation-low CRC...
  62. pmc Hormone therapy increases risk of ulcerative colitis but not Crohn's disease
    Hamed Khalili
    Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Gastroenterology 143:1199-206. 2012
    ..The role of postmenopausal hormone therapy on risk of Crohn's disease (CD) and ulcerative colitis (UC) is unclear...
  63. pmc Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 367:1596-606. 2012
    ....
  64. pmc Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study
    Aya Kuchiba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 104:415-20. 2012
    ..9 and 7.1, respectively, per 100,000 person-years. This molecular pathological epidemiology study supports a role of energy metabolism in colorectal cancer pathogenesis...
  65. pmc Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:3140-9. 2010
    ..We hypothesized: 1) A(1) allele would confer greater risk than A(2) allele, 2) protective effect of the O allele would be equivalent for O01 and O02 variants, 3) secretor phenotype would modify the association with risk...
  66. pmc A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
    ..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors...
  67. pmc Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803
    Kimmie Ng
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:4354-63. 2010
    ..Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown...
  68. pmc Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells
    Natsumi Irahara
    Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115, USA
    J Mol Diagn 12:177-83. 2010
    ..9) in leukocyte DNA. In conclusion, bisulfite conversion and PCR-pyrosequencing assay can measure LINE-1 methylation in macrodissected colon cancer, normal colon, and blood DNA, and may be useful in clinical and research settings...
  69. pmc A cohort study of p27 localization in colon cancer, body mass index, and patient survival
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital, Boston, and Harvard Medical School 02115, USA
    Cancer Epidemiol Biomarkers Prev 18:1849-58. 2009
    ..08). In conclusion, p27 alterations in colon cancer are associated with superior prognosis. Adverse prognostic effect of obesity seems limited to patients with nuclear p27 expression, suggesting a host-tumor interaction...
  70. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  71. pmc Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer
    Noriko Tanaka
    Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
    Am J Pathol 177:2731-40. 2010
    ..Our novel data suggest two distinct perturbations, resulting in differential locus-specific propensity of CpG methylation...
  72. ncbi request reprint TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 38:614-20. 2007
    ....
  73. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..We studied the efficacy of cetuximab therapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oral inhibitor of the tyrosine kinase domain of the epidermal growth factor receptor...
  74. ncbi request reprint Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 19:1083-90. 2006
    ..KRAS mutations were not concordant in any synchronous neoplasia pair. In conclusion, epigenetic alterations at CIMP-specific promoter CpG islands in synchronous colorectal neoplasias likely have both random and nonrandom components...
  75. pmc A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
    Clin Cancer Res 15:4431-8. 2009
    ....
  76. ncbi request reprint Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women
    Andrew T Chan
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Natl Cancer Inst 97:917-26. 2005
    ..We assessed dietary iron intake and genetic and biochemical markers of iron status in a prospective, nested case-control study of women enrolled in the Nurses' Health Study...
  77. ncbi request reprint Physical activity and survival after colorectal cancer diagnosis
    Jeffrey A Meyerhardt
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3527-34. 2006
    ..Physically active individuals have a lower risk of developing colorectal cancer but the influence of exercise on cancer survival is unknown...
  78. pmc CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations
    Shuji Ogino
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    J Mol Diagn 8:582-8. 2006
    ..In conclusion, CIMP-low colorectal cancer is associated with male sex and KRAS mutations. The hypothesis that CIMP-low tumors are different from CIMP-high and CIMP-0 tumors needs to be tested further...
  79. pmc Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:4109-15. 2008
    ..However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied...
  80. pmc A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 100:1734-8. 2008
    ..In conclusion, tumoral LINE-1 hypomethylation is independently associated with shorter survival among colon cancer patients...
  81. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  82. ncbi request reprint Dietary patterns and pancreatic cancer risk in men and women
    Dominique S Michaud
    Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    J Natl Cancer Inst 97:518-24. 2005
    ..Dietary patterns have been associated with fasting insulin levels and risk of diabetes. To determine whether dietary patterns are associated with pancreatic cancer risk, we analyzed data from two large prospective cohort studies...
  83. pmc STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1452-62. 2011
    ..Although the STAT3 signaling pathway is a potential drug target, clinical, pathologic, molecular, or prognostic features of STAT3-activated colorectal cancer remain uncertain...
  84. pmc Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer
    Takako Kawasaki
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Neoplasia 9:569-77. 2007
    ..Cytoplasmic beta-catenin is associated with COX-2 overexpression, supporting the role of cytoplasmic beta-catenin in stabilizing PTGS2 (COX-2) mRNA...
  85. ncbi request reprint Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women
    Esther K Wei
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 97:684-92. 2005
    ..However, no previous epidemiologic studies have directly evaluated the association of plasma PLP with risk for colorectal neoplasia...
  86. doi request reprint Activity of sunitinib in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:3403-10. 2008
    ..We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients...
  87. ncbi request reprint Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study
    Charles S Fuchs
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4779-86. 2007
    ....
  88. ncbi request reprint Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Charles S Fuchs
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:807-14. 2003
    ..We prospectively compared the efficacy and tolerability of two irinotecan regimens (once a week for 4 weeks followed by a 2-week rest period [weekly] v once every 3 weeks) in such patients...
  89. ncbi request reprint Adjuvant therapy in gastric cancer: can we prevent recurrences?
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Channing Laboratory, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Oncology (Williston Park) 17:714-21, 728; discussion 728-9, 732-3. 2003
    ..We focus attention on the recent widespread acceptance of adjuvant chemoradiotherapy, based on the results of Intergroup trial 0116. Future strategies incorporating different modalities of treatment will be outlined...
  90. ncbi request reprint A prospective study of aspirin use and the risk of pancreatic cancer in women
    Eva S Schernhammer
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 96:22-8. 2004
    ....
  91. ncbi request reprint Chemotherapy options for gastric cancer
    Jeffrey A Meyerhardt
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Radiat Oncol 12:176-86. 2002
    ..As a greater understanding of the molecular basis of gastric cancer is gained, the inclusion of biologic-based therapies will hopefully advance our ability to treat patients with gastric cancer more effectively...
  92. ncbi request reprint Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study
    Esther K Wei
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 97:1688-94. 2005
    ..Because both adiposity and insulin resistance have been associated with risk of colorectal cancer, we hypothesized that adiponectin is associated with colorectal carcinogenesis...
  93. ncbi request reprint Prospective study of predictors of vitamin D status and cancer incidence and mortality in men
    Edward Giovannucci
    Department of Medicine, Harvard Medical School, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 98:451-9. 2006
    ....
  94. pmc Prospective weight change and colon cancer risk in male US health professionals
    Lau Caspar Thygesen
    Department of Nutrition, Harvard School of Public Health, Boston, USA
    Int J Cancer 123:1160-5. 2008
    ..5. Our results add support that overweight and obesity are modifiable risk factors for colon cancer among men and suggest that weight has an important influence on colon cancer risk even in later life...
  95. pmc Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer
    Karin B Michels
    Obstetrics and Gynecology Epidemiology Center, Brigham and Women s Hospital, and Harvard Medical School, 221 Longwood Ave, Boston, MA 02115, USA
    J Natl Cancer Inst 97:282-92. 2005
    ..Cohort studies have not revealed such an association but were limited in size. We explored the association between consumption of coffee and tea and the incidence of colorectal cancer in two large prospective cohorts of women and men...
  96. ncbi request reprint Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women
    Dominique S Michaud
    Harvard School of Public Health, Kresge 920, 677 Huntington Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:138-47. 2005
    ..High intakes of GL, fructose, and sucrose were related to an elevated colorectal cancer risk among men. For women, however, these factors did not seem to increase the risk of colorectal cancer...
  97. ncbi request reprint Plasma vitamin D metabolites and risk of colorectal cancer in women
    Diane Feskanich
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 13:1502-8. 2004
    ..We therefore examined risk in relation to plasma concentrations of these vitamin D metabolites...
  98. ncbi request reprint Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  99. ncbi request reprint Current and ongoing trials with irinotecan in the United States
    Charles S Fuchs
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:9-17. 2003
  100. ncbi request reprint Night-shift work and risk of colorectal cancer in the nurses' health study
    Eva S Schernhammer
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 95:825-8. 2003
    ..84 to 1.19) and 1.35 (95% CI = 1.03 to 1.77), respectively (P(trend) =.04). These data suggest that working a rotating night shift at least three nights per month for 15 or more years may increase the risk of colorectal cancer in women...
  101. ncbi request reprint Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort
    John Z Ayanian
    Division of General Medicine and Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:1293-300. 2003
    ..This population-based study was designed to assess use of these treatments in clinical practice...